Archive · 2 Jan 2026
South Korea Develops AI for Custom Cancer Vaccine
Scientists in South Korea have created a special computer program that can help make personalized cancer vaccines.
This program looks for unique markers in a person's cancer that can teach their body's immune system to fight the cancer.
The team from KAIST and Neogenlogic says this can help prevent cancer from coming back.
They published their findings in a science journal and are planning to test this in real patients starting in 2027.
The program has been checked with lots of data and is now part of a bigger tool called DeepNeo.
The scientists are excited because this could be a big step in making better cancer treatments.
KAIST and Neogenlogic developed an AI model to identify neoantigens for personalized cancer vaccines.
The AI model predicts which neoantigens will trigger a robust B cell response.
Findings were published in the Dec. 3 edition of Science Advances.
The technology has been validated against large-scale genomic datasets and clinical trial data.
Clinical trials are planned for 2027, with an IND submission to the FDA.
- Who
- KAIST and Neogenlogic joint research team
- What
- Developed an AI model for personalized cancer vaccines
- When
- Published in Science Advances on Dec. 3, clinical trials planned for 2027
- Where
- South Korea
- Why
- To identify neoantigens unique to each cancer patient for immune system training and prevention of cancer recurrence
- Research Team
- KAIST and Neogenlogic
- AI Model Purpose
- Identify neoantigens for personalized cancer vaccines
- Publication
- Science Advances (Dec. 3 edition)
- Clinical Trials
- Planned for 2027
- FDA Submission
- Investigational New Drug (IND) submission planned
- Technology Validation
- Against large-scale genomic datasets and clinical trial data
- Integration
- AI framework integrated into DeepNeo discovery engine